Z-505, an Oral Ghrelin Receptor Agonist, Attenuates Anorexia After Total Gastrectomy in Rats

Anorexia is a serious problem in patients with gastric cancer who have undergone gastrectomy. Ghrelin, an orexigenic hormone primarily secreted from the stomach, has been proposed to prevent anorexia. Significant reduction in plasma ghrelin levels after gastrectomy may contribute to lack of appetite...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of surgical research 2020-02, Vol.246, p.527-534
Main Authors: Shiomi, Yoshihiro, Yoshimura, Makoto, Hori, Yuko, Ohira, Yuta, Nagahama, Kenji, Ozaki, Tomoko, Takei, Mineo, Tanaka, Takao, Uno, Tomohide
Format: Article
Language:English
Subjects:
Amides - administration & dosage
Animals
Anorexia
Anorexia - blood
Anorexia - drug therapy
Anorexia - etiology
Arcuate Nucleus of Hypothalamus - cytology
Arcuate Nucleus of Hypothalamus - drug effects
Arcuate Nucleus of Hypothalamus - metabolism
Body Weight - drug effects
Disease Models, Animal
Eating - drug effects
Gastrectomy - adverse effects
Ghrelin
Ghrelin - blood
Humans
Hypothalamic arcuate nucleus
Male
Neurons - drug effects
Neurons - metabolism
Proto-Oncogene Proteins c-fos - metabolism
Pyrrolidines - administration & dosage
Rats
Rats, Sprague-Dawley
Receptors, Ghrelin - agonists
Stomach Neoplasms - surgery
Total gastrectomy
Z-505
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anorexia is a serious problem in patients with gastric cancer who have undergone gastrectomy. Ghrelin, an orexigenic hormone primarily secreted from the stomach, has been proposed to prevent anorexia. Significant reduction in plasma ghrelin levels after gastrectomy may contribute to lack of appetite and weight loss. In this study, we investigated the effects of Z-505, a ghrelin receptor agonist, on anorexia after total gastrectomy (TG) in a rat model. Male Sprague–Dawley rats were used to establish a TG model, and then sham-operated (control) and TG rats were randomly assigned to four subgroups receiving administration of Z-505 (100 mg/kg, p.o., once daily) or vehicle for 14 d from day 14 to day 27 after TG. The food intake, body weight, and fat weight were evaluated during the test period. Moreover, the neuronal activity in the hypothalamus was evaluated on day 21 to investigate the mechanism of action of Z-505. In TG rats, Z-505 significantly improved the decrease in cumulative food intake induced by the surgery over 14 d (TG + vehicle; 213.8 ± 15.3 g, n = 12 versus TG + Z-505; 258.2 ± 13.1 g, n = 14, P 
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2019.09.035